Phase 2 Brain Cancer Trial, Recruiting NCT05050929 Sponsor: British Columbia Cancer Agency Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT05050929
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been diagnosed with a solid (non-blood) cancer
  • People who have cancer that has spread to the brain (brain metastases), regardless of size
  • People with any number of brain metastases — whether previously untreated or still growing after prior treatment — that can all be identified and targeted for treatment
  • People who also have cancer present outside the brain
  • People whose disease severity score, based on a specific brain metastasis assessment tool, is 2.0 or lower (confirm with trial site)
  • People who are able to complete a standard quality-of-life questionnaire called the EQ-5D-5L
  • People who are willing and able to attend regular scans for follow-up monitoring
  • People for whom treatment can begin within 14 days of joining the trial
  • People with a general health and function score (Karnofsky Performance Score) of 50 or above, meaning they are able to care for themselves at least some of the time (confirm with trial site)

Who may not be able to join:

  • People who are unable to have a brain MRI scan
  • People who have had whole-brain radiation therapy less than 3 months before joining the trial
  • People with a widespread form of cancer spread across the lining of the brain and spinal cord (limited spread to the outer brain lining may still be permitted — confirm with trial site)
  • People who have multiple sclerosis
  • People whose neurological condition is getting worse despite taking steroid medication
  • People for whom surgery or a targeted radiation treatment called stereotactic radiosurgery is considered appropriate
  • People with germ cell tumours or cancers that started in the brain
  • People with certain autoimmune or connective tissue conditions — such as lupus or scleroderma — that are not currently in remission
  • People with another serious illness or medical condition that the trial doctor believes would make participation unsafe or unmanageable
  • People who are pregnant
  • People who could potentially father or carry a child and are not willing to use highly effective contraception during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alan Nichol, MD, BC Cancer Vancouver

Phone: 604-877-6000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
British Columbia Cancer Agency
Registry
ClinicalTrials.gov
Start date
1 July 2022
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Survival Time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov